Treatment response and association with survival in the combined cohorts.
tumor, tumors
TUMOR, TUMORS
Similar to the analysis of the initial dose–determination cohort (Of the 92/117 (78.6%) patients who survived to the 2-month landmark time, 14 were responders (all irradiated tumors responded), 8 were nonresponders (at least 1 irradiated tumor progressed), and the remaining 70 patients had a mixed response (not all irradiated tumors responded but none progressed). The 1-year OS was 71% for responders, 42% for mixed-responders, and 0% for nonresponders (